Sign In
Buy ANIX
$3.42
-0.140 (-3.93%)
At Close: Jul 31, 2026
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
07:30am, Monday, 12'th Feb 2024
Dose escalation for fourth patient follows successful completion of first cohort SAN JOSE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
08:50am, Monday, 29'th Jan 2024
Conference Investment Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology SAN JOSE, Calif. , Jan. 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
07:55am, Tuesday, 23'rd Jan 2024
Broad coverage extended to Japan and related regions SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnol
Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024
09:00am, Wednesday, 10'th Jan 2024
SAN JOSE, Calif. , Jan. 10, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of
Anixa Biosciences to Present at Biotech Showcase 2024
07:15am, Thursday, 14'th Dec 2023
SAN JOSE, Calif. , Dec. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
12:26pm, Monday, 11'th Dec 2023
Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
06:00pm, Wednesday, 06'th Dec 2023
– Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – – Vaccine was s
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
04:05pm, Wednesday, 06'th Dec 2023
– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m.
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology
08:30am, Monday, 27'th Nov 2023
SAN JOSE, Calif. , Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
11:02am, Thursday, 09'th Nov 2023
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference
08:30am, Tuesday, 31'st Oct 2023
Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial SAN JOSE, Calif. , Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnolog
SAN JOSE, Calif. , Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
Bears are Losing Control Over ANIXA BIOSCIENCES INC (ANIX), Here's Why It's a 'Buy' Now
11:16am, Friday, 13'th Oct 2023
ANIXA BIOSCIENCES INC (ANIX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
08:30am, Friday, 13'th Oct 2023
- With no dose-limiting toxicities observed, treatment of second dose cohort to begin SAN JOSE, Calif. , Oct. 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX
ANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Thursday, 21'st Sep 2023
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
